Search Results
Your search for it matches 15526 pages
Showing 13101 - 13150REVEL: Winning a Questionable Race
The investigators and sponsors of the phase III REVEL trial should be congratulated and probably commiserated. In this large study, reported by Garon and colleagues in The Lancet and reviewed in this issue of The ASCO Post, 1,253 patients with advanced non–small cell lung cancer (NSCLC) were...
Significant Improvement in Overall Survival With Second-Line Addition of Ramucirumab to Docetaxel in Stage IV NSCLC
In the phase III REVEL trial reported in Lancet, Edward B. Garon, MD, of the David Geffen School of Medicine at UCLA/Translational Research in Oncology–US Network, Los Angeles, and colleagues found that the addition of the antiangiogenic vascular endothelial growth factor receptor (VEGFR)-2...
Early Study Finds BRCA-Mutated Pancreatic Cancer Responds to PARP Inhibition Trio
Two-thirds of patients with advanced pancreatic adenocarcinoma who harbored BRCA mutations responded to the combination of veliparib, cisplatin, and gemcitabine in a phase IB trial that is paving the way for future studies of novel poly(ADP-ribose) polymerases (PARP) inhibitors in this challenging...
CTNeoBC Analysis: Response to Neoadjuvant Chemotherapy Varies by Breast Tumor Subtype
Women who achieve a pathologic complete response (pCR) to neoadjuvant chemotherapy rarely have local or regional recurrence of breast cancer, but this largely depends on tumor subtype, which remained an independent predictor of locoregional recurrence when pathologic response was taken into account ...
Fertility Preservation Suggested With Triptorelin in Long-Term Study
Young women with early breast cancer may be more likely to resume menses and become pregnant when treated with a luteinizing hormone–releasing hormone (LH-RH) analog (also known as a gonadotropin-releasing hormone [GnRH] analog) along with chemotherapy, according to the final follow-up of...
With Breast-Conserving Surgery, Margin Status Not a Factor in Recurrence
In a chart review of 754 early-stage breast cancer patients undergoing breast-conserving surgery, margin status did not impact risk of locoregional recurrence or breast cancer-specific survival, though it did predict for overall survival, as did numerous other factors. Tumor biology remained the...
Expert Point of View: Harold Burstein, MD
Harold Burstein, MD, Associate Professor of Medicine at Dana-Farber Cancer Institute, Boston, spoke to The ASCO Post about the multidisciplinary discussion of margin assessment during the 2014 Breast Cancer Symposium. Should Oncologists Be Concerned? “There is a real art to being a good...
How Accurate Is the Pathologic Assessment of the Partial Mastectomy Specimen?
The pathologic evaluation of lumpectomy margins is “fraught with problems and pitfalls,” said Stuart J. Schnitt, MD, Director of Anatomic Pathology at Beth Israel Deaconess Medical Center and Professor of Pathology at Harvard Medical School, Boston, who was part of a multidisciplinary discussion of ...
Pathologic Complete Response: Understanding the Subtleties
In the neoadjuvant treatment of breast cancer, the importance of achieving a pathologic complete response (pCR) varies substantially by breast cancer subtype. Patients are increasingly interested in this outcome, but it means different things to different patients, according to two breast cancer...
Managing Resistance to Targeted Agents: The Future of NSCLC Therapy
The bane of treating non–small cell lung cancer (NSCLC) patients with druggable mutations has been the development of resistance to targeted agents. New compounds are meeting the challenge of treating resistant disease, according to Fadlo R. Khuri, MD, FACP, Professor and Chair of Hematology and...
Exciting Highlights in Several Types of Lymphoma Presented at Best of ASCO
Antibody-drug conjugates are being tested against several types of lymphomas and for some of these agents, “activity is quite impressive,” Andrew M. Evens, DO, MSc, reported at the recent Best of ASCO meeting in Chicago. Dr. Evens, Professor of Medicine, Chief, Division of Hematology/Oncology, and...
Best of ASCO Seattle Proves Engaging, Provocative
This year’s Best of ASCO meeting held in Seattle featured topics that both riveted attendees and pushed their buttons, according to program chair Alan P. Venook, MD, of the University of California, San Francisco. “I am extremely pleased with the quality of the presentations from the faculty, but...
Determining Androgen-Deprivation Therapy
Determining an appropriate course of androgen-deprivation therapy in patients with prostate cancer is complex. For patients with high-risk features, 4 to 6 months of androgen-deprivation therapy helps, but 28 to 36 months is better in terms of disease control and overall survival. In the study by...
Duration of Androgen-Deprivation Therapy for Patients With High-Risk Prostate Cancer
Optimal duration of androgen-deprivation therapy as part of primary therapy for prostate cancer continues to be an important question. Two well-conducted studies reported recently at the 56th Annual Meeting of the American Society for Radiation Oncology (ASTRO) provide data that can help inform...
Radiation Therapy Improves 10-Year Survival for Patients With Early Hodgkin Lymphoma, but Frequently Omitted in Treatment Plans
Adding consolidation radiation therapy to chemotherapy significantly improves 10-year survival in patients with stage I and II Hodgkin lymphoma, according to a large observational study based on the National Cancer Database (NCDB). Yet over that same 10-year period, radiation therapy use declined...
Expert Point of View: Benjamin Movsas, MD
Benjamin Movsas, MD, Chair of Radiation Oncology at Henry Ford Hospital in Detroit, served as moderator at a press conference where the two SBRT studies by Timmerman et al and Ashworth et al were reported.1,2 Dr. Movsas said that SBRT is a promising approach, noting that the therapy facilitates...
Stereotactic Body Radiation Therapy Benefits Patients With Early-Stage Inoperable or Advanced Oligometastatic Lung Cancer
The door is open for expanded use of stereotactic body radiation therapy (SBRT) in patients with inoperable early-stage lung cancer and for patients with oligometastatic stage IV non-small cell lung cancer (NSCLC), according to results of two studies presented at the 56th Annual Meeting of the...
Tough Questions About Health-Care Reform Put Economist in Hot Seat
Although diverse stakeholders agree that health reform is needed, there is little consensus on the specifics of that reform. Best of ASCO Seattle attendees put a number of pointed questions to health economist Rena Conti, PhD, of the University of Chicago, asking about thorny issues such as cost...
Health-Care Reform Is Changing the Oncology Landscape
Value-based health-care reform is happening. We have to get on board,” Rena Conti, PhD, a health economist at the University of Chicago, advised attendees of the Best of ASCO Seattle meeting. She discussed highlights from Annual Meeting sessions that addressed the impact of the Affordable Care Act...
Hippocratic Oath
I swear by Apollo the physician, and Asclepius, and Hygieia and Panacea and all the gods and goddesses as my witnesses, that, according to my ability and judgement, I will keep this Oath and this contract: To hold him who taught me this art equally dear to me as my parents, to be a partner in life...
Relevance of the Hippocratic Oath in the 21st Century
On the face of it, the idea that a code of professional conduct dating to the ancient Iron Age could possibly retain any relevance in the current era of “Big Data,” religious and cultural pluralism, trillion-dollar government budgets, and nanotechnology seems preposterous. Yet the well-publicized...
Expert Point of View: Benjamin Movsas, MD
Benjamin Movsas, MD, Chair of Radiation Oncology at Henry Ford Hospital in Detroit, served as moderator at a press conference where the two SBRT studies by Timmerman et al and Ashworth et al were reported.1,2 Dr. Movsas said that SBRT is a promising approach, noting that the therapy facilitates...
MHC-Matched Graft-vs-Host Disease Requires Recipient Intestinal Barrier Loss and Natural Killer Cell Inactivation
Although available data indicate an association among pretransplantation conditioning intensity, intestinal barrier loss, and severity of graft-vs-host disease, the multiple effects of irradiation and other types of conditioning have made it difficult to precisely identify the role of intestinal...
NCI Awards $2 Million Grant to University of Pittsburgh School of Dental Medicine to Study How Cancer Spreads to Bone
With a $2 million, 5-year grant from the National Cancer Institute (NCI), researchers at the University of Pittsburgh School of Dental Medicine will examine the molecular mechanisms that allow certain cancers, particularly multiple myeloma, to spread to the bone. The project could lead to new...
In Memoriam: Kelly Traw
Regretfully, The ASCO Post has learned that Kelly Traw, 49, passed away on September 2, 2014, at Johns Hopkins Hospital in Baltimore. While her obituary did not mention a cause of death, it said that, “She will be greatly missed by her extended family and by the many friends who supported her...
AACR Honors Zhu Chen, MD, PhD, for Distinguished Public Service and Global Impact in Cancer Research
The American Association for Cancer Research (AACR) honored Zhu Chen, MD, PhD, with the 2014 AACR Award for Distinguished Public Service and Global Impact in Cancer Research in Biomedical Science at the AACR’s inaugural meeting in China, called New Horizons in Cancer Research: Harnessing...
A History of Medical Oncology
BOOKMARK Title: Therapeutic Revolution: The History of Medical Oncology From Early Days to the Creation of the SubspecialtyAuthor: Pierre R. BandPublisher: Bentham SciencePublication date: 2014Price: $39.00 (eBook); $78.00 (print on demand); 213 pagesAvailable at: eurekaselect.com According to...
Clinical Trials Actively Recruiting Patients With Lung Cancer
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies of people with lung neoplasms, including stage I and II small cell and non–small cell lung cancers. The studies include phase Ib, II, III, observational, and interventional trials...
Professional Associations Collaborate to Launch Stereotactic Radiosurgery Patient Registry
The American Association of Neurological Surgeons (AANS) and the American Society for Radiation Oncology (ASTRO) are partnering to launch and support a national registry for stereotactic radiosurgery (SRS) treatments. The partnership was announced recently at the ASTRO Annual Meeting. The SRS...
$1 Million Raised in Honor of 40th Anniversary of Milestone
Gifts totaling $1 million in honor of the 40th anniversary of the cure for testicular cancer were recently announced at a celebration for the physician scientist who developed the treatment. Family, friends, colleagues, and men grateful for their lives gathered at the Indianapolis Museum of Art to...
Treating Testicular Cancer in 2014
Testicular cancer is one of oncology’s true success stories. It is a highly treatable disease, usually curable, that most often develops in young and middle-aged men. Despite the success in testicular cancer, there are still clinical challenges ranging from staging to optimum therapeutic...
Expert Point of View: Andrew D. Zelenetz, MD, PhD
I am a believer in intriguing preliminary data that suggests we can modify the poor outcome associated with non–[germinal center B-cell] lymphoma—for example, using R2-CHOP (lenalidomide [Revlimid] and rituximab [Rituxan] plus cyclophosphamide, doxorubicin, vincristine, and prednisone), ibrutinib...
Beyond R-CHOP for Lymphoma
The R-CHOP regimen (rituximab [Rituxan] plus cyclophosphamide, doxorubicin, vincristine, and prednisone) was a major advance in treating diffuse large B-cell lymphoma, but experts are seeking to up the ante and identify ways to continue to improve outcomes beyond that achieved with R-CHOP. “We are...
Experts Debate the Need for Upfront vs Late Stem Cell Transplant in Multiple Myeloma
With powerful new drugs capable of achieving sustained and deep remissions in multiple myeloma, the role of upfront stem cell transplantation is being questioned by experts, who debated the pros and cons at the National Comprehensive Cancer Network (NCCN) 9th Annual Congress on Hematologic...
Variety of Adjuvant Strategies Explored in HER2‑Positive and Other Breast Cancer Types
Adjuvant trastuzumab (Herceptin) was shown to be effective in patients with breast cancers ≤ 2 cm, regardless of estrogen receptor status, in a meta-analysis1 of five chemotherapy trials, but a “pressing question” remaining is whether T1a/b, N0 tumors warrant the use of adjuvant trastuzumab, Andrew ...
For Triple-Negative Breast Cancer, Adding Carboplatin to Anthracycline/Taxane Produces Benefit, but How Much?
Combination chemotherapy for triple-negative breast cancer is anthracycline- and taxane-based and has not really changed much in the past 10 years, but “we are starting to see emerging data with selective activity of platinum agents,” Priyanka Sharma, MD, told participants at the Best of ASCO...
CancerLinQ™ Receives Major Commitment From CTCA®
The Conquer Cancer Foundation of ASCO has received a major commitment of support for the development of CancerLinQ™ from Cancer Treatment Centers of America, Inc (CTCA), a national network of five cancer hospitals. The donation is the largest received to date in support of CancerLinQ, a...
Illumination and Innovation: Transforming Data Into Learning
"Illumination” is a provocative word, evoking as it does the banishment of the darkness of ignorance by the light of new knowledge. Today, we are benefiting from a steady stream of new knowledge about the molecular basis of cancer and the interaction between host and tumor immunology. The concept...
Despite Potential to Overwhelm, Surveys Still Essential Research Tool
The age of the Internet and worldwide connectivity has made it easier than ever to send out surveys to a wide audience quickly and easily. This ease of access can make surveys an affordable and readily available research tool for independent investigators, but it can also make surveys an...
Lenvatinib Receives Priority Review Designation for Advanced Thyroid Cancer
The U.S. Food and Drug Administration (FDA) has given Priority Review designation to the New Drug Application for lenvatinib mesylate as a treatment for progressive radioactive iodine–refractory differentiated thyroid cancer. Lenvatinib is an oral multiple receptor tyrosine kinase inhibitor with a...
Expert Point of View: Bertrand Tombal, MD, PhD
The formal discussant of the study presented by James et al at the ESMO 2014 Congress was Bertrand Tombal, MD, PhD, Chairman of the Division of Urology and Associated Professor of Physiology at Université Catholique de Louvain, Brussels. He praised the STAMPEDE trial as “wonderful, because it...
Radiotherapy Should Be Added to Hormone Therapy in Node-Positive Prostate Cancer
Node-positive prostate cancer has typically been excluded from clinical trials, leaving oncologists with little evidence to guide management for this group of patients. A study presented at the European Society for Medical Oncology (ESMO) 2014 Congress sheds light on this issue, providing the...
Long-Term Results of COU-AA-302 Confirm Abiraterone Benefit
Final results of the COU-AA-302 trial continue to support the survival benefit of abiraterone acetate (Zytiga) in men with chemotherapy-naive metastatic castration-resistant prostate cancer, often referred to as the “predocetaxel space.” “The study met the overall survival endpoint and all...
Expert Point of View: Stefan Zimmermann, MD
Mesothelioma has been the focus of a graveyard of negative trials,” said Stefan Zimmermann, MD, Senior Oncologist at the Hematology/Oncology Clinic, HFR Fribourg– Cantonal Hospital, Fribourg, Switzerland, during the ESMO 2014 Congress. “The epidemiology of mesothelioma is complicated, with a long ...
Local Treatments Fail to Improve Survival in Mesothelioma
The prognosis for malignant pleural mesothelioma remains dim, despite attempts to intensify treatment in the phase II SAKK 17/04 trial and other studies. The results of SAKK 17/04, presented at the 2014 European Society for Medical Oncology (ESMO) Congress in Madrid, showed that the addition of...
Expert Point of View: Florian Scotté, MD, PhD
The study was well performed and was a good representative sample of patients with cachexia,” said formal discussant Florian Scotté, MD, PhD, a medical oncologist in the Department of Oncology at the Georges Pompidou European Hospital, Paris, regarding the study presented by Temel et al at the ESMO ...
Novel Oral Agent Treats Cachexia in Patients With Non–Small Cell Lung Cancer
For the first time, studies show that a drug is effective in treating several domains of cancer-related cachexia. Oral anamorelin increased lean body mass, achieved weight gain, and improved quality of life in patients with cancer-related cachexia in two pivotal phase III studies presented together ...
Women Underrepresented in Oncology Leadership Positions, Greek Survey Shows
A growing number of oncologists in Greece are female, but women continue to be underrepresented in leadership positions, according to a survey reported at the ESMO 2014 Congress. “In Greece, and across Europe, women oncologists still find it hard to access leadership or academic positions,” said...
Expert Point of View: Ignacio Melero, MD, PhD
As discussant of the nivolumab paper presented by Weber et al at the ESMO Presidential Symposium, Ignacio Melero, MD, PhD, of the Universidad de Navarra in Spain, said “We are presented today with very exciting clinical data. The only disappointment is that the survival data are not mature.” Dr....
Nivolumab Yields ‘Impressive’ Duration of Response as Late-Line Melanoma Treatment
Nivolumab yielded an “impressive” duration of response when used as second- or third-line treatment for patients with advanced melanoma, according to Jeffrey S. Weber, MD, of the Moffitt Cancer Center in Tampa, Florida, who presented preliminary results of a phase III trial at the European Society...
